Resolves YES if Judge Matthew Kacsmaryk in Amarillo, Texas grants an injunction to remove mifepristone from the U.S. market completely. Resolves NO if he denies that motion, or if he decides on some other action which only limits its availability.

See https://www.npr.org/2023/03/15/1163670457/abortion-pill-kacsmaryk-mifepristone-texas

Was the FDA wrong to approve a drug that's used in nearly all medication abortions in the U.S. — and should the drug, mifepristone, be taken off the market? Those questions were argued in court Wednesday, in a case heard by controversial federal Judge Matthew Kacsmaryk in Amarillo, Texas.

If the lawsuit succeeds, it could have sweeping repercussions — for abortion providers and patients across the nation, as well as for the FDA's drug-approval process.

The plaintiffs have filed a motion seeking a preliminary injunction to remove mifepristone from the U.S. market or limit its availability. The FDA has asked the judge to deny that motion, saying the lawsuit isn't likely to succeed. In court filings, the agency also said that while injunctions are commonly issued to preserve the status quo, in this case, an injunction "would upend the status quo" that has held for more than 20 years.

Wednesday's proceeding was a hearing on the injunction motion, with each side given two hours to present their arguments.